Moreover, to harness the immune system to preserve survival and increase the efficacy of immunotherapy in low immunogenic cancers, the combination of PALM, as a potential ICD inducer, and immunotherapy (e.g., anti-CD47 antibody and anti-CTLA-4) may be suitable to improve therapeutic outcomes, as suggested by the literature83–86. The gene discussed is CD47; the disease is cancer.